Supplements

Yifei Sanjie Pill reduces the 2-year progression rate of high-risk pulmonary nodules in adults with mixed ground-glass nodules ≤8 mm.

This multicenter RCT protocol evaluates YFSJ versus placebo for preventing progression of high-risk pulmonary nodules over 2 years. The primary outcome is progression rate defined by ≥2 mm increase in diameter, ≥1 mm increase in solid component, or new solid component. The study enrolled 589 participants and will analyze results using Kaplan-Meier and Cox regression.

Last updated: Jul 19, 2026•1 RCTs•📖 Read as article →

Evidence Score

Evidence Score42/100
Human RCT★★☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Clinical Study on the Prevention of High-Risk Pulmonary Nodule Progression With Yifei Sanjie Pill: Protocol for a Multicenter Randomized Controlled Trial.

observational

An B, Lin J, Wang J, Chen Z, Guan M, Li Y, Qi X, Sun L, Lin L · JMIR research protocols (2026)

Participants: N/A
Duration: 2 years follow-up (6 months treatment)
Intervention: Yifei Sanjie Pill (YFSJ) optimized formula granules, 2 packets twice daily for 6 months
Outcome: 2-year pulmonary nodule progression rate (increase in longest diameter ≥2 mm, increase in solid component ≥1 mm, or appearance of new solid component)
Effect Size: N/A
Population: Adults aged 18–80 years with single or multiple mixed ground-glass nodules measuring ≤8 mm

Result:

PubMed: 42456132DOI: 10.2196/78534

Mechanism Graph

YFSJ is an 8-herb traditional Chinese medicine formula
↓
Previously studied as adjunctive treatment for non-small cell lung cancer
↓
May modulate plasma biomarkers and malignancy risk index
↓
Result: potential reduction in nodule progression

Limitations

  • ⚠Results are not yet available; this is a protocol paper
  • ⚠The study is ongoing with final analysis expected in 2028
  • ⚠Placebo-controlled but blinding details not fully described

Frequently Asked Questions

What is Yifei Sanjie Pill?▼

YFSJ is an 8-herb traditional Chinese medicine formula previously studied as an adjunctive treatment for non-small cell lung cancer.

Who is eligible for this trial?▼

Adults aged 18–80 years with single or multiple mixed ground-glass nodules ≤8 mm.

What is the primary outcome of the study?▼

The 2-year pulmonary nodule progression rate, defined as an increase in lesion diameter ≥2 mm, increase in solid component ≥1 mm, or new solid component.

When will the results be available?▼

Database lock and primary analysis are planned for early 2028, with first results expected in spring or summer 2028.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.An B, Lin J, Wang J, Chen Z, Guan M, Li Y, Qi X, Sun L, Lin L. "Clinical Study on the Prevention of High-Risk Pulmonary Nodule Progression With Yifei Sanjie Pill: Protocol for a Multicenter Randomized Controlled Trial.." JMIR research protocols, 2026. PMID: 42456132 DOI: 10.2196/78534
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.